DGAT1 and breast carcinoma: Inhibition of DGAT1 activity by a DGAT1 inhibitor (A922500) significantly reduced TG synthesis, cell proliferation, and the migratory ability of breast cancer MDA-231 cells, accompanied by decreased expression levels of cyclin D1 and Zeb1 [124].